A multiple sclerosis drug is manufactured at the Biogen Idec plant in Cambridge, Mass.
Essdras M Suarez | The Boston Globe | Getty Images
Check out the companies making headlines midday Monday:
Biogen — A Morgan Stanley analyst upgraded the biopharma company to overweight from underweight and predicted a 30% rally in the stock over the next 12 months. The analyst expects Wall Street to “price in higher odds of success for aducanumab, Biogen’s investigational drug which is the first potential disease modifying therapy for Alzheimer’s disease.” Biogen shares rose more than 3%.
Amazon — Shares of the e-commerce giant gained 0.5% after several Wall Street firms raised their price target on the stock, including Bank of